Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; 'Awaiting Execution With Key Pipeline Opportunities'
November 10, 2017 9:29 AM ESTBMO Capital raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $17.00 (from $16.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes an improved price targets, as the company reported third quarter earnings per share and... More
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Piper Jaffray
November 9, 2017 7:52 AM ESTPiper Jaffray raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining an Overweight rating.
Analyst David Amsellem notes solid performance from the base business. The analyst believes there is still room for meaningful value creation in the context of an EV/2018E EBITDA of 10x-11x.
... MoreRaymond James Downgrades Amphastar Pharmaceuticals (AMPH) to Market Perform
November 9, 2017 4:40 AM ESTRaymond James downgraded Amphastar Pharmaceuticals (NASDAQ: AMPH) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.
Shares of Amphastar Pharmaceuticals closed at $17.81 yesterday.
... MoreAmphastar Pharma (AMPH) Tops Q3 EPS by 5c
November 8, 2017 4:08 PM ESTAmphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.07, $0.05 better than the analyst estimate of $0.02. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $57.2 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More